Maureen Newman is a science columnist for Pulmonary Hypertension News. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.
A new Sponsored Research Agreement between OncoSec Medical Inc. and Massachusetts General Hospital will allow researchers from both facilities to collaborate and investigate the mechanisms of action behind OncoSec’s clinical ... Read more
A collaboration of researchers from Roswell Park Cancer Institute in Buffalo, University at Buffalo School of Medicine, and Innate Immunotherapeutics in New Zealand recently tested the effects of immunizing tumor-bearing ... Read more
On November 8th, a representative from Lycera Corp., a biopharmaceutical company based in Ann Arbor, Michigan, presented the poster, “Novel Synthetic RORγ Agonist Compounds as a Potential Anti-tumor Therapeutic Approach,” ... Read more
A “striking” new study that made the cover of the current Cancer Research journal identified an oral biologic medication that successfully treats chronic, precancerous inflammation in the intestine of an ... Read more
Innate Pharma, a biopharmaceutical company based in Marseille, France, announced that it has fully enrolled 150 patients for its Phase 2 clinical trial “Efficacy Study of Anti-KIR Monoclonal Antibody as ... Read more